GenrAb Completes $5.6 Million Financing to Accelerate Development of its Lead Antibody Therapy (TGM-010) and Expand Pipeline of Neuroprotective Candidates
GenrAb advances TGM-010, a neuron-targeting antibody, with new seed funding.
Entries by Roberta
GenrAb will be presenting at the IC3 Conference in Arlington, TX on October 3rd
GenrAb will present antibody therapy data and company updates at IC³ Conference in Arlington, TX, on October 3rd.
Team Expansion
GenrAb expands leadership team with Martin Devenport as COO and Dr. Jonghee Han as a specialist in neurology.
GenrAb receives Golden Tickets sponsored by Boehringer Ingelheim & Otsuka Pharmaceutical Company
GenrAb wins two prestigious Golden Tickets from Boehringer Ingelheim and Otsuka, securing lab space for antibody development.
GenrAb Expands its Exclusive License and Sponsored Research Agreements with UTSW
GenrAb expands exclusive license with UTSW, adding over 250 anti-neuronal antibodies to its growing pipeline.
Issuance of US Patents that cover GenrAb’s lead antibody therapy (TGM-010)
GenrAb secures US patents for its lead antibody TGM-010, advancing neuroprotective therapy development.
GenrAb is awarded the North Texas Therapeutics Innovator of the Year for 2023
GenrAb wins 2023 North Texas Therapeutics Innovator of the Year for pioneering antibody therapy at Innovation Days.
GenrAb establishes its HQ @ BioLabs in Dallas TX
GenrAb selects BioLabs @ Pegasus Park, Dallas, as its HQ for antibody therapy development and expansion.